Louis Hiotis, MD
Internal Medicine · Chicago, ILNPI 1710980339
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 182 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,705 and has fallen 85.8% since, to $243 in 2025.
Across 182 payments — averaging $18.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$580
- Novo Nordisk$558
- Merck$305
- Pfizer$285
- Amgen$256
- GSK$229
- plus $1K from 19 others
Across 5 payments — averaging $9101.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$34K
- AstraZeneca$11K
- Regeneron$165
What the payments were for
- Food & beverage$3,396100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 27 | $580 |
| Novo Nordisk | 29 | $558 |
| Merck | 16 | $305 |
| Pfizer | 16 | $285 |
| Amgen | 14 | $256 |
| GSK | 15 | $229 |
| Exact Sciences | 6 | $158 |
| Johnson & Johnson(2 entities) | 5 | $124 |
| E.r. Squibb & Sons, L.L.C. | 8 | $116 |
| AstraZeneca | 9 | $113 |
| CSL Behring | 4 | $108 |
| Lilly USA, LLC | 5 | $87 |
| Gilead | 5 | $84 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $59 |
| Teva Pharmaceuticals USA, Inc. | 4 | $53 |
| Boehringer Ingelheim | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| AbbVie | 2 | $37 |
| Seqirus USA Inc | 2 | $32 |
| Abbott | 1 | $28 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $26 |
| Medtronic | 1 | $18 |
| Radius Health, Inc. | 1 | $17 |
| Kaleo, Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
How this compares
$3,396 in reported general payments places this provider in the 85th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 38 | $36,120 |
| OzempicSemaglutide | 25 | $33,172 |
| JardianceEmpagliflozin | 22 | $31,470 |
| MounjaroTirzepatide | 18 | $22,540 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $19,958 |
| MyrbetriqMirabegron | 16 | $10,732 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,834 |
| Atorvastatin Calcium | 187 | $2,359 |
| Rosuvastatin Calcium | 155 | $2,352 |
| Ezetimibe | 44 | $1,412 |
| Metoprolol Succinate | 70 | $1,344 |
| Tamsulosin Hcl | 52 | $1,165 |
| Amlodipine Besylate | 94 | $1,089 |
| Losartan Potassium | 90 | $1,063 |
| Pantoprazole Sodium | 62 | $1,015 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $285 | $36,12038 claims |
| Novo NordiskOzempic | $558 | $33,17225 claims |
| Boehringer IngelheimJardiance | $52 | $31,47022 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $229 | $24,79228 claims |
| Lilly USA, LLCMounjaro | $87 | $22,54018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Chicago
- Merle DiamondChicago$1.1M
- Robert KushnerChicago$516K
- Romeo UrsuaChicago$420K
- Peter O DonnellChicago$318K
- George UrbanChicago$258K
- Kristen PallokChicago$256K
- George NissanChicago$252K
- Luke LaffinChicago$162K
- Daniel CatenacciChicago$161K
- Hiren ShahChicago$144K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.